Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy

Journal of Immunotherapy

Volumn 41, Issue 7, 2018, Pages 350-358

  Shalabi, Haneen ^a   Wolters, Pamela L ^a   Martin, Staci ^a   Toledo Tamula, Mary Anne ^b   Roderick, Marie Claire ^a   Struemph, Kari ^a   Kane, Eli ^a   Yates, Bonnie ^a   Delbrook, Cindy ^a   MacKall, Crystal L ^c   Lee, Daniel W ^d   Fry, Terry J ^a   Shah, Nirali N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Chimeric antigen receptor therapy; neurotoxicity; pediatric acute leukemia

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; BLINATUMOMAB; CD19 ANTIBODY; CD22 ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TOCILIZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CD22 ANTIGEN; CYTOKINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMNESIA; ARTICLE; ATAXIC APHASIA; ATTENTION; AUDITORY HALLUCINATION; BRAIN ATROPHY; CANCER RADIOTHERAPY; CAREGIVER; CEREBELLAR ATAXIA; CEREBROSPINAL FLUID ANALYSIS; CHECKLIST; CHILD; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITION; COGNITION ASSESSMENT; COGNITIVE FLEXIBILITY; CONFUSION; CONGENITAL BLOOD VESSEL MALFORMATION; CRANIAL NERVE PARALYSIS; CYTOKINE RELEASE SYNDROME; DEPRESSION; DIFFUSE LARGE B CELL LYMPHOMA; DIPLOPIA; DISEASE SEVERITY; DISORIENTATION; EXECUTIVE FUNCTION; EXECUTIVE FUNCTION TEST; FEMALE; FEVER; HUMAN; LEUKEMIA RELAPSE; LUMBAR PUNCTURE; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCESSING SPEED; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SEIZURE; TREATMENT RESPONSE; VISUAL HALLUCINATION; WHOLE BODY RADIATION; WHOLE BRAIN RADIOTHERAPY; WORKING MEMORY; YOUNG ADULT; ADOPTIVE IMMUNOTHERAPY; ADVERSE DRUG REACTION; ADVERSE EVENT; BLOOD; BRAIN; CLINICAL TRIAL; DEMENTIA ASSESSMENT; DRUG EFFECT; DRUG RESISTANCE; HALLUCINATION; IMMUNOLOGY; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SPINE; TOXICITY AND INTOXICATION;

ADOLESCENT; ADULT; BRAIN; CHILD; CONFUSION; CYTOKINES; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HALLUCINATIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS AND DEMENTIA TESTS; NEUROTOXICITY SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RECURRENCE; SIALIC ACID BINDING IG-LIKE LECTIN 2; SPINE; YOUNG ADULT;

EID: 85052085628     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000241     Document Type: Article

References (30)

1. Stone JB, DeAngelis LM. Cancer-treatment-induced neurotoxicity-focus on newer treatments. Nat Rev Clin Oncol. 2016;13:92-105.
2. Cole PD, Kamen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev. 2006;12:174-183.
3. Winick N. Neurocognitive outcome in survivors of pediatric cancer. Curr Opin Pediatr. 2011;23:27-33.
4. Krull KR, Brinkman TM, Li C, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31:4407-4415.
5. Hardy KK, Embry L, Kairalla JA, et al. Neurocognitive functioning of children treated for high-risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies: a report from the children's oncology group. J Clin Oncol. 2017;35:2700-2707.
6. Soffietti R, Trevisan E, Ruda R. Neurologic complications of chemotherapy and other newer and experimental approaches. Handb Clin Neurol. 2014;121:1199-1218.
7. Verstappen CC, Heimans JJ, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003;63:1549-1563.
8. Schiff D, Kesari S, Wen PY. Cancer Neurology in Clinical Practice Neurologic Complications of Cancer and its Treatment Current Clinical Oncology, 2nd ed. Totowa, NJ: Humana Press; 2008:1; Online resource (xvi, 636 p., 5 p. of plates).
9. Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57-66.
10. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517-528.
11. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-1517.
12. Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123:2625-2635.
13. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunother-apy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404-1419.
14. Tasian SK, Gardner RA. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol. 2015;6:228-241.
15. Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803-1813.
16. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165-1174.
17. Weintraub S, Dikmen SS, Heaton RK, et al. Cognition assessment using the NIH Toolbox. Neurology. 2013;80(Suppl 3): S54-S64.
18. Wechsler. Wechsler Adult Intelligence Scale-IV. Administration and Scoring Manual. San Antonio, TX: NCS Pearson Inc.; 2008.
19. Wechsler. Wechsler Intelligence Scale for Children-V. Admin-istration and Scoring Manual. Bloomington, MN: NCS Pearson Inc.; 2014.
20. Martin SW, Shah P, Delbrook NN, et al. D.W No consistent neurocognitive declines are observed with CD19 CAR T cell therapy for children with acute lymphocytic leukemia: Preliminary findings. Presented at 2015 Conference on Immunother-apy in Pediatric Oncology; 2015.
21. Youngstrom EA, Findling RL, Danielson CK, et al. Discriminative validity of parent report of hypomanic and depressive symptoms on the General Behavior Inventory. Psychol Assess. 2001;13:267-276.
22. Byrne JM, Backman JE, Smith IM. Developmental assessment-the clinical use and validity of parental report. J Pediatr Psychol. 1986;11:549-559.
23. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.
24. Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2017; 24:20-28.
25. Hessl D, Sansone SM, Berry-Kravis E, et al. The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions. J Neurodev Disord. 2016;8:35.
26. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47-62.
27. Herman MA, Tremont-Lukats I, Meyers CA, et al. Neuro-cognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol. 2003;26: 273-279.
28. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21:3557-3558.
29. Davila ML, Bouhassira DC, Park JH, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol. 2014;99:361-371.
30. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemo-therapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540-549.